Novo Nordisk to invest €432m in Athlone manufacturing site
Novo Nordisk plans to expand manufacturing capacity for oral GLP-1 therapies in Europe. On 2 March 2026, the company announced a €432 million investment in its tabletting facility in Monksland, Athlone, Ireland.
Added capacity for current and future GLP-1 therapies
According to the company, the expansion is intended to provide additional manufacturing capacity for existing and future GLP-1 treatments. The Athlone site focuses on oral products and is expected to strengthen supply for markets outside the US.
Upgrade and retrofit of the existing facility
The investment is set to fund upgrades and retrofit work at the current plant. The overall project covers the 45-acre site (about 18 hectares). Construction has already started, with completion planned in phases from the end of 2027 through 2028.
Jobs and site footprint
The facility currently employs 260 people. Novo Nordisk expects the project to create up to 500 construction jobs during the build-out.
Company background
Novo Nordisk is headquartered in Denmark and focuses on treatments for serious chronic diseases. The company employs about 68,800 people globally and markets its products in around 170 countries.
Advertisement
Data-privacy settings
We use cookies on our website to improve the service we offer. The information helps us to understand how our visitors use our site. But some cookies are even necessary for the proper function of the website. These are marked as "essential" in the details.
Cookies by Microsoft Clarity are used for website analytics, heatmaps, and session recordings. They help us understand how visitors interact with our website so we can improve usability and performance.
